<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096014</url>
  </required_header>
  <id_info>
    <org_study_id>18-749</org_study_id>
    <nct_id>NCT04096014</nct_id>
  </id_info>
  <brief_title>Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy</brief_title>
  <official_title>Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are
      high. Hyperammonemia contributes significantly to encephalopathy and occurs because of
      impaired hepatic ureagenesis and increased skeletal muscle proteolysis. We propose a
      randomized, 6-month nutritional intervention in cirrhotic patients who have had at least 1
      admission for hepatic encephalopathy within the last 6 months. We hypothesize that a
      combination of late evening and early morning protein supplement (Ensure Enlive) will
      decrease recurrent hepatic encephalopathy and consequent readmission rates by lowering
      skeletal muscle proteolysis and improved lean body mass.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if decreasing nocturnal fasting by protein supplements will change readmission rates.</measure>
    <time_frame>Day 0 &amp; Day 180</time_frame>
    <description>Change in number of readmissions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Ensure Enlive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure Enlive</intervention_name>
    <description>The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.</description>
    <arm_group_label>Ensure Enlive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Of Care</intervention_name>
    <description>The subjects in the Standard of care group will continue to receive the standard clinical therapy.</description>
    <arm_group_label>Ensure Enlive</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  cirrhosis diagnosed by clinical history and liver biopsy and/or clinical, biochemical
             and imaging evidence of cirrhosis

          -  at least 1 hospitalization for documented HE within the last 12 months.

          -  abdominal CT scan anytime in the past

        Exclusion Criteria:

          -  Patients with MELD score &gt; 35

          -  end stage organ failure (major dysfunction requiring organ support)

          -  kidney injury defined by a creatinine &gt; 2 mg/dl or rise in creatinine by 0.5 gm/dl
             from baseline that is unresponsive to withholding diuretics and intravenous albumin
             administration (1 gm/kg up to 100 gm/day)

          -  active malignancy

          -  uncontrolled diabetes mellitus with A1c&gt;9.5 (to avoid altered muscle protein
             metabolism

          -  medications (anabolic steroids, corticosteroids) that affect skeletal muscle mass

          -  recent gastrointestinal surgery within past 12 months

          -  ongoing infection (positive blood or other body fluid cultures)

          -  active gastrointestinal bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annette C Bellar</last_name>
    <phone>2166365247</phone>
    <phone_ext>2166365247</phone_ext>
    <email>bellara@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Bellar, BS</last_name>
      <phone>216-445-6268</phone>
      <email>bellara@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Revathi Penumatsa</last_name>
      <email>penumar@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivasan Dasarathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

